Michael J. Fox Foundation for Parkinson’s Research Improved Biomarkers and Clinical Outcome Measures Program

Michael J. Fox Foundation for Parkinson’s Research Improved Biomarkers and Clinical Outcome Measures Program Deadline: Pre-Proposals Due: December 3, 2014 – 6pm US ET One-to-three-year grants to develop robust and precise biomarkers (imaging, physiological, genomic, biochemical assays, etc.) and/or clinical outcome measures that can inform therapeutic trial designs and interpretation of trial results.  The biomarkers and outcome measures should be aimed at informing clinical trial decisions. The overarching goal of this initiative is to facilitate the development of biomarker and clinical outcome measures that enable objective decisions for advancing therapies through various stages of clinical development. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) seeks to support research that will develop improved biomarker tools and clinical outcome measures to assist in clinical trial design, execution and interpretation of results. Funding will focus on projects that improve the ability to enrich subject populations in clinical trials and/or determine whether experimental treatments are modifying the course of the disease, its symptoms, or its progression. MJFF is also interested in supporting projects to determine target engagement/target modulation and pharmacodynamic response, especially for high priority therapeutic targets like alpha synuclein, LRRK2, parkin, and glucocerebrosidase. See the Purpose section below for further det...
Source: ScanGrants feed - Category: Research Authors: Source Type: funding